What does Immunovant, Inc. do?
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous…
What is Immunovant, Inc.'s P/E and P/B ratio?
Immunovant, Inc. has a P/E ratio of -10.3 and a P/B ratio of 8.17.
What is Immunovant, Inc.'s debt-to-equity ratio?
Immunovant, Inc. has a debt-to-equity ratio of 0.00.
How much does Immunovant, Inc. owe compared with what it owns?
Immunovant, Inc. owes $0.14 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Immunovant, Inc.'s Positivity rank?
Immunovant, Inc. is ranked #4,828 of 6,775 companies globally and #2,502 of 4,000 in United States on PositoAI, with a Positivity Score of 18,940.
Does Immunovant, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Immunovant, Inc..
Where can I read the latest news about Immunovant, Inc.?
Recent headlines about Immunovant, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Immunovant, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Immunovant, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.